P
P. M. van Hagen
Researcher at Erasmus University Rotterdam
Publications - 90
Citations - 6841
P. M. van Hagen is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Medicine & Somatostatin. The author has an hindex of 28, co-authored 65 publications receiving 5850 citations. Previous affiliations of P. M. van Hagen include University of Genoa & Hebrew University of Jerusalem.
Papers
More filters
Journal ArticleDOI
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
TL;DR: Preoperative chemoradiotherapy improved survival among patients with potentially curable esophageal or esophagogastric-junction cancer and the regimen was associated with acceptable adverse-event rates.
Journal ArticleDOI
Anti-TNF-alpha therapy for sight threatening uveitis.
TL;DR: Anti-TNF-α treatment may be of value in the treatment of uveitis and in patients with Behçet’s disease, leading to suppression of ocular inflammation, vasculitis, and improvement of vision in the majority.
Journal ArticleDOI
In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.
Willem H. Bakker,Eric P. Krenning,Jean Claude Reubi,Wouter A.P. Breeman,B. Setyono-Han,M. de Jong,P. P. M. Kooij,C. Bruns,P. M. van Hagen,P. Marbach,T. J. Visser,J. Pless,S. W. J. Lamberts +12 more
TL;DR: Because of its relatively long effective half-life, [111In-DTPA-D-Phe1]-octreotide is a radionuclide-coupled somatostatin analogue which can be used to visualize som atostatin receptor-bearing tumors efficiently after 24 hr, when interfering background radioactivity is minimized by renal clearance.
Journal ArticleDOI
The effect of etanercept on Graves' ophthalmopathy: a pilot study
TL;DR: This study strongly suggests that etanercept may suppress the clinical signs in GO, but randomized controlled trials are needed to further evaluate the effect of anti-TNF treatment and to compare its side-effects with those of corticosteroids.
Journal ArticleDOI
Somatostatin and the immune and haematopoetic system ; a review
P. M. van Hagen,E. P. Krenning,Dirk Jan Kwekkeboom,Jean Claude Reubi,Vd. P. J. Anker‐Lugtenburg,Bob Löwenberg,S. W. J. Lamberts +6 more
TL;DR: The presence of SS-R in lymphoid neoplasm cells and in diseases involving activated mononuclear leukocytes allows the visualization of these diseases using octreotide scintigraphy and warrants studies on the efficacy of treatment withOctreotide of patients suffering from these diseases.